drug_type
RELEVANT_DRUG
intervention_type
Biological
drug_description
Autologous CAR-T cells targeting CD22 on B-lineage cells; CAR activation induces T-cell effector functions to kill CD22-positive malignant B cells, potentially causing B-cell aplasia.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
Immunotherapy, Adoptive
drug_category
CAR T
drug_class
Cellular Therapy
drug_delivery_route
Intravenous
drug_mechanism_of_action
Autologous T cells are genetically engineered to express a chimeric antigen receptor that binds CD22 on B-lineage cells. Antigen engagement activates CAR signaling (CD3zeta with co-stimulatory domains), leading to T-cell activation, proliferation, cytokine release, and perforin/granzyme-mediated killing of CD22-positive malignant B cells, with potential on-target B-cell aplasia.
drug_name
CD22-directed autologous CAR-T cells
nct_id_drug_ref
NCT06647329